K-ras mutations and cetuximab in colorectal cancer.

scientific article

K-ras mutations and cetuximab in colorectal cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJMC082346
P698PubMed publication ID19228630

P2093author name stringGiampietro Gasparini
Antonio Marchetti
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectcolorectal cancerQ188874
cetuximabQ420296
P304page(s)833-4; author reply 835-6
P577publication date2009-02-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleK-ras mutations and cetuximab in colorectal cancer.
P478volume360

Reverse relations

cites work (P2860)
Q37396252A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting
Q27851527Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones
Q37916396Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review
Q54415409Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
Q34565052Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions
Q39416581Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method
Q21142734Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
Q35986751Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Q39606707Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis
Q55689709Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
Q37015715The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers

Search more.